- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01669616
Point of Service Diabetes Screening Evaluation (POSSE)
January 13, 2013 updated by: VeraLight, Inc.
The primary objective of the trial is to collect SCOUT DS, random capillary glucose and Hemoglobin A1c measurements from subject 18 years of age or older.
Study Overview
Status
Completed
Conditions
Detailed Description
The objectives of this study are to compare the accuracy of SCOUT versus random capillary glucose and several diabetes risk assessment questionnaires for detection of HbA1C-defined dysglycemia.
Study Type
Observational
Enrollment (Actual)
667
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- Blue Cross Blue Shield of Louisiana
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Attendees of Blue Cross Blue Shield Wellness Event
Description
Inclusion Criteria:
- 18 years of age or older
Exclusion Criteria:
- Known to be pregnant (self-reported)
- Receiving dialysis or known renal compromise
- Known to have photosensitivity
- Taking medications that fluoresce
- Have scars, any tattoos, rashes or other disruption/discoloration on the left volar forearm
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To compare the accuracy of SCOUT DS versus random capillary glucose and several diabetes risk assessment questionnaires for detection of HbA1c-defined dysglycemia.
Time Frame: one week
|
one week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Andrea Barrack, MD, Blue Cross Blue Shield of Louisiana
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2012
Primary Completion (Actual)
January 1, 2013
Study Completion (Actual)
January 1, 2013
Study Registration Dates
First Submitted
July 23, 2012
First Submitted That Met QC Criteria
August 16, 2012
First Posted (Estimate)
August 21, 2012
Study Record Updates
Last Update Posted (Estimate)
January 15, 2013
Last Update Submitted That Met QC Criteria
January 13, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VL-2723
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Non-Insulin Dependent
-
Procter and GambleTerminatedNon-Insulin-dependent Diabetes MellitusUnited States
-
Inha University HospitalCompletedNon Insulin Dependent Diabetes MellitusKorea, Republic of
-
VeraLight, Inc.CompletedDiabetes Mellitus, Non-Insulin DependentUnited States
-
National Center for Complementary and Integrative...CompletedDiabetes Mellitus, Non-Insulin Dependent | Non-Insulin DependentUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedDiabetes Mellitus, Type II | Diabetes Mellitus, Non Insulin DependentUnited States, Poland, Bulgaria, India, Malaysia, Romania, Canada, Russian Federation, Argentina, Puerto Rico, Czech Republic, United Kingdom, Mexico
-
Merck Sharp & Dohme LLCCompletedDiabetes Mellitus, Non-Insulin-Dependent | Type 2 Diabetes Mellitus, Non Insulin Dependent
-
National Nutrition and Food Technology InstituteCompletedNon Insulin Dependent DiabetesIran, Islamic Republic of
-
German Diabetes CenterHeinrich-Heine University, DuesseldorfCompletedObesity | Non-insulin-dependent Diabetes MellitusGermany
-
Lille Catholic UniversityUniversity Hospital, LilleTerminatedNon-insulin-dependent DiabetesFrance
-
National Nutrition and Food Technology InstituteUnknownNon Insulin Dependent DiabetesIran, Islamic Republic of